Esperion Therapeutics Inc (NASDAQ: ESPR) on Friday, soared 2.02% from the previous trading day, before settling in for the closing price of $2.47. Within the past 52 weeks, ESPR’s price has moved between $1.16 and $3.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 7.64%. The company achieved an average annual earnings per share of 84.83%. With a float of $195.06 million, this company’s outstanding shares have now reached $197.03 million.
Considering the fact that the conglomerate employs 240 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc is 1.00%, while institutional ownership is 65.81%. The most recent insider transaction that took place on Nov 19 ’24, was worth 427. In this transaction Chief Commercial Officer of this company sold 197 shares at a rate of $2.17, taking the stock ownership to the 162,355 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Officer proposed sale 197 for $2.17, making the entire transaction worth $427.
Esperion Therapeutics Inc (ESPR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 84.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 1.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach 0.32 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Compared to the last year’s volume of 6.14 million, its volume of 4.49 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 80.33%. Additionally, its Average True Range was 0.16.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 78.99%, which indicates a significant decrease from 89.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.50% in the past 14 days, which was higher than the 69.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.03, while its 200-day Moving Average is $2.22. Nevertheless, the first resistance level for the watch stands at $2.56 in the near term. At $2.59, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.65. If the price goes on to break the first support level at $2.47, it is likely to go to the next support level at $2.41. Should the price break the second support level, the third support level stands at $2.38.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 506.58 million based on 197,035K outstanding shares. Right now, sales total 116,330 K and income totals -209,250 K. The company made 51,630 K in profit during its latest quarter, and -29,520 K in sales during its previous quarter.
